Pharma Strategy Blog https://pharmastrategyblog.com Mon, 07 Aug 2017 13:00:16 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.4 Developing a predictive biomarker for PARP inhibition https://pharmastrategyblog.com/2014/02/developing-a-predictive-biomarker-for-parp-inhibition.html/ Fri, 07 Feb 2014 15:24:54 +0000 http://pharmastrategyblog.com/?p=6273 Update on RAF resistance in metastatic melanoma https://pharmastrategyblog.com/2014/01/update-on-raf-resistance-in-metastatic-melanoma.html/ Fri, 31 Jan 2014 17:38:39 +0000 http://pharmastrategyblog.com/?p=6259 Red and Green Flags in cancer research and development https://pharmastrategyblog.com/2014/01/red-and-green-flags-in-cancer-research-and-development.html/ https://pharmastrategyblog.com/2014/01/red-and-green-flags-in-cancer-research-and-development.html/#comments Fri, 24 Jan 2014 17:26:06 +0000 http://pharmastrategyblog.com/?p=6240 https://pharmastrategyblog.com/2014/01/red-and-green-flags-in-cancer-research-and-development.html/feed/ 2 Will intermittent dosing transform TKI therapy in cancer research? https://pharmastrategyblog.com/2014/01/will-intermittent-dosing-transform-tki-therapy-in-cancer-research.html/ Fri, 17 Jan 2014 19:09:22 +0000 http://pharmastrategyblog.com/?p=6232 Making a difference in NHL and CLL: an interview with Dr Carol Gallagher https://pharmastrategyblog.com/2014/01/making-a-difference-in-nhl-and-cll-an-interview-with-dr-carol-gallagher.html/ Fri, 10 Jan 2014 18:09:49 +0000 http://pharmastrategyblog.com/?p=6220 Medivation announce interim results of PREVAIL in pre-chemotherapy CRPC https://pharmastrategyblog.com/2013/10/medivation-announce-interim-results-of-prevail-in-pre-chemotherapy-crpc.html/ https://pharmastrategyblog.com/2013/10/medivation-announce-interim-results-of-prevail-in-pre-chemotherapy-crpc.html/#comments Tue, 22 Oct 2013 20:21:23 +0000 http://pharmastrategyblog.com/?p=6183 https://pharmastrategyblog.com/2013/10/medivation-announce-interim-results-of-prevail-in-pre-chemotherapy-crpc.html/feed/ 2 Can Merck make an impact in pancreatic cancer? https://pharmastrategyblog.com/2013/10/can-merck-make-an-impact-in-pancreatic-cancer.html/ Tue, 22 Oct 2013 10:22:39 +0000 http://pharmastrategyblog.com/?p=6177 Removing the PD-1 brake enhances the effect on adoptive CAR T cells https://pharmastrategyblog.com/2013/10/removing-the-pd-1-brake-enhances-the-effect-on-adoptive-car-t-cells.html/ Wed, 16 Oct 2013 15:47:34 +0000 http://pharmastrategyblog.com/?p=6166 The CLL Landscape is rapidly a’changing… https://pharmastrategyblog.com/2013/10/the-cll-landscape-is-rapidly-achanging.html/ https://pharmastrategyblog.com/2013/10/the-cll-landscape-is-rapidly-achanging.html/#comments Thu, 10 Oct 2013 13:05:31 +0000 http://pharmastrategyblog.com/?p=6155 https://pharmastrategyblog.com/2013/10/the-cll-landscape-is-rapidly-achanging.html/feed/ 1 Update on KRAS and NRAS mutations in colorectal cancer https://pharmastrategyblog.com/2013/09/update-on-kras-and-nras-mutations-in-colorectal-cancer.html/ Thu, 19 Sep 2013 16:07:51 +0000 http://pharmastrategyblog.com/?p=6146